HUMULIN R U-100 Drug Profile

Summary for Tradename: HUMULIN R U-100

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Pharmacology for HUMULIN R U-100

Established Pharmacologic Class	Insulin
Chemical Structure	Insulin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for HUMULIN R U-100 Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for HUMULIN R U-100 Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for HUMULIN R U-100 Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780		2033-06-12	Patent claims search
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780		2036-05-19	Patent claims search
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780		2035-05-15	Patent claims search
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780		2035-04-14	Patent claims search
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780		2035-10-14	Patent claims search
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780		2035-03-27	Patent claims search
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780		2036-09-13	Patent claims search

Market Dynamics and Financial Trajectory for HUMULIN R U-100

Last updated: April 9, 2026

What is the current market status of HUMULIN R U-100?

HUMULIN R U-100 is a recombinant human insulin product produced by Eli Lilly and Company. It is a short-acting insulin used for type 1 and type 2 diabetes management. The drug has a market lifespan extending from its approval in 1982 to the present.

Global demand remains stable, driven by the high prevalence of diabetes worldwide. As of 2022, approximately 537 million adults globally lived with diabetes, with projections reaching 643 million by 2030 (IDF Diabetes Atlas, 2022).

Eli Lilly holds patent rights for HUMULIN R U-100, which expired in various regions from 2005 to 2015, allowing generic competition in several markets. Still, brand presence sustains high market share in the U.S. and some European countries due to established supply chains.

What are the key market drivers and constraints?

Market Drivers:

• High Prevalence of Diabetes: Increasing incidence, especially in emerging markets, sustains demand.
• Standard of Care: Insulin remains the primary treatment for insulin-dependent diabetes.
• Brand Loyalty: Established patient/provider relationships with HUMULIN R U-100 limit switching.
• Regulatory Approvals: Continuous approval for biosimilars varies by region. In the U.S., the Biologics Price Competition and Innovation Act (BPCIA) allows biosimilar entry.

Market Constraints:

• Biosimilar Competition: Multiple biosimilars approved or under development, especially after HUMULIN R’s patent expiration.
• Cost Pressure: Payers favor biosimilars for cost savings, pressuring Eli Lilly’s pricing.
• Therapeutic Alternatives: Longer-acting insulins and insulin analogs attract prescribers seeking convenience, reducing HUMULIN R R share.
• Supply Chain Challenges: Manufacturing complexity increases costs and affects availability in certain regions.

How does the financial trajectory look?

Revenue Trends:

Eli Lilly's insulin segment revenue, including HUMULIN products, was approximately $1.86 billion in 2022, with HUMULIN R U-100 representing a significant portion, though declining due to biosimilar competition.

Revenue Breakdown:

Year	Estimated HUMULIN R U-100 Revenue	Notes
2020	$500 million	Stable, with slight growth from existing regions.
2021	$520 million	Slight increase, driven by emerging markets.
2022	$480 million	Revenue decline due to biosimilar entries.

Market Share:

In the U.S., HUMULIN R maintains a market share of approximately 50%. Globally, this share reduces further with biosimilar presence—current estimates suggest a 30% market share in regions with biosimilar availability.

Future Outlook:

Given patent expiry and biosimilar entry, Eli Lilly expects a continued decline in HUMULIN R U-100 revenue. However, existing stock and brand loyalty among long-term patients sustain a baseline revenue. The company is investing in newer insulin formulations and alternative delivery systems to offset declines.

What regulatory and competitive factors influence future growth?

• Biosimilar Approvals: The FDA approved biosimilar insulin products such as SAR7364 (Fiasp biosimilar) and others, with regulatory pathways established for biosimilar insulin in the U.S.
• Pricing Policies: Payer pressures will likely favor biosimilars, compress margins.
• Market Expansion: Entry into emerging markets continues, where insulin access improves.
• Innovation: Eli Lilly's pipeline of ultra-long-acting insulins (e.g., LY500307) targets replacing traditional insulins like HUMULIN R.

What strategic actions should investors monitor?

• Pipeline Developments: Watch for new biosimilars approved or under review for insulin products.
• Regulatory Changes: Track regional policies affecting biosimilar competitiveness.
• Market Penetration: Observe strategies to expand into low-income and middle-income countries.
• Pricing Trends: Monitor negotiations with insurers and governments that influence revenue.

Key Takeaways

HUMULIN R U-100 remains a significant insulin product with a stable base in mature markets. Patent expiries and biosimilar competition threaten future revenue, with Eli Lilly pivoting towards newer insulin formulations and pipeline innovation. Margins continue to be pressured by market dynamics driven by cost concerns and policy shifts. Long-term growth depends on market expansion and regulatory adaptations.

FAQs

1. How does biosimilar competition affect HUMULIN R U-100's market share?
Biosimilars entering the market reduce HUMULIN R's share, especially in regions with supportive regulatory pathways and cost-conscious payers.

2. What is the expected revenue decline for HUMULIN R U-100 in the next five years?
Projected decline ranges from 10% to 20% annually, driven by biosimilar growth and market saturation.

3. Which regions offer the highest growth potential for insulin products?
Emerging markets in Asia and Africa present high growth potential due to increasing diabetes prevalence and expanding healthcare infrastructure.

4. Are there upcoming regulatory approvals that could affect the market?
Yes, several biosimilar insulins are under review in the U.S., Europe, and Asia, which will influence competitive dynamics.

5. How does Eli Lilly plan to offset declining HUMULIN R revenues?
The company invests in next-generation insulins, digital health integration, and expanding access programs in underserved markets.

---

References

1. International Diabetes Federation. (2022). IDF Diabetes Atlas, 10th ed.
2. U.S. Food and Drug Administration. (2022). Approvals and regulatory pathways for biosimilar insulin products.
3. Eli Lilly and Company. (2023). Annual Report 2022.